More recently, new guidelines for the use of cetuximab and panitumumab treatment in CRC patients supported the analysis of the mutational status of both KRAS and NRAS genes and BRAF in wild-type RAS cancers [6]. Here, KRAS is linked to colorectal carcinoma.